Massachusetts Financial Services Co. MA Purchases 10,366 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Massachusetts Financial Services Co. MA increased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,877,917 shares of the biotechnology company's stock after buying an additional 10,366 shares during the quarter. Massachusetts Financial Services Co. MA owned about 3.08% of Ascendis Pharma A/S worth $292,692,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Ascendis Pharma A/S by 54.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock valued at $375,226,000 after purchasing an additional 960,504 shares during the last quarter. Capital International Investors increased its position in Ascendis Pharma A/S by 35.7% in the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after purchasing an additional 753,859 shares during the last quarter. RA Capital Management L.P. increased its position in Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the last quarter. Vestal Point Capital LP increased its position in Ascendis Pharma A/S by 108.0% in the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock worth $71,588,000 after purchasing an additional 270,000 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in Ascendis Pharma A/S by 4.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after purchasing an additional 193,688 shares during the last quarter.

Ascendis Pharma A/S Trading Up 0.4%

NASDAQ:ASND traded up $0.65 during mid-day trading on Wednesday, hitting $175.40. 426,384 shares of the company's stock traded hands, compared to its average volume of 505,082. The firm has a 50 day moving average of $168.88 and a two-hundred day moving average of $154.15. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00. The firm has a market capitalization of $10.72 billion, a price-to-earnings ratio of -27.93 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. As a group, equities research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ASND. Citigroup upped their target price on Ascendis Pharma A/S from $213.00 to $243.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Bank of America increased their price objective on Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a report on Monday, June 9th. Evercore ISI increased their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Wedbush increased their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Finally, Royal Bank Of Canada increased their price objective on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and a consensus target price of $223.07.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.